Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMTX-100 CF3, is a topical formulation anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
Details : AMTX-100 CF3, its leading drug candidate, is known for its ability to transport across membranes, address inflammation and modulate immune mediated diseases instead of simply inhibiting inflammation.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : AmbioPharm
Deal Size : Undisclosed
Deal Type : Partnership
Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : AmbioPharm
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $18.0 million
Deal Type : Series A Financing
Amytrx Therapeutics Raises $18M For New Therapeutic Interventions of Atopic Dermatitis
Details : The funding is dedicated to continuing clinical research on the use of their next-generation anti-inflammatory therapeutic peptide platform, AMTX-100, across several skin inflammatory disorders in adults and adolescents.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $18.0 million
Deal Type : Series A Financing
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amytrx is developing AMTX-100, a new anti-inflammatory therapeutic platform, which has broad potential in multiple inflammatory, autoimmune, and metabolic diseases.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMTX-100 CF
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : AMTX-100 CF
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Amarex Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable